CDKL5 and craniodiaphyseal dysplasia: Based on the promising results obtained, we next assessed FRAX486 therapeutic efficacy in vivo on heterozygous Cdkl5‐KO female (Cdkl5‐Het) mice, the model that better reproduces the genetic and hormonal milieu of CDD patients.30